Donanemab: A Promising Alzheimer's Treatment from Eli Lilly
Eli Lilly's experimental Alzheimer's drug, donanemab, has shown a 35% reduction in decline of thinking skills in people with early-stage Alzheimer's in an 18-month trial. The drug targets and clears away beta-amyloid, a sticky protein that builds up into brain-clogging plaques. However, the drug also comes with risks of brain side effects, which caused the deaths of three participants in the study. Lilly plans to release more details at an international Alzheimer's meeting this summer and is seeking FDA approval of the drug.